CAS No.: 154229-18-2

Molecular formula: C26H33NO2

Molecular weight: 391.55

Overview: Abiteron acetate was initially developed by the British Cancer Research Institute and BTG, and then transferred the global development right and listing right to Cougar Bio-pharmaceutical Company (now a subsidiary of Johnson&Johnson). Abitherone acetate 201Chemicalbook was approved for the first time in the United States on April 28, 2011. Its trade name is Zytiga, oral tablet, 250mg, combined with prednisone for the treatment of castration resistant prostate cancer (cRPC), which cannot be controlled by docetaxel.

Use: scientific research reagent, widely used in molecular biology, pharmacology and other scientific research. Abitherone acetate is converted into Abitherone in vivo, an androgen biosynthesis inhibitor, which inhibits Chemicalbook 17 α- Hydroxylase/C17,20-lyase (CYP17). It is expressed in testicular, adrenal and prostate tumor tissues and is required for androgen biosynthesis.